Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).

• Egile Nagusiak: Jaime Altcheh (Egilea), Luis Castro (Egilea), Juan C Dib (Egilea), Ulrike Grossmann (Egilea), Erya Huang (Egilea), Guillermo Moscatelli (Egilea), Jimy José Pinto Rocha (Egilea), Teresa Estela Ramírez (Egilea), CHICO Study Group (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2021-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Nifurtimox is a recommended treatment for Chagas disease, but data from treated children are limited. We investigated the efficacy, safety and tolerability of nifurtimox administered as divisible, dispersible 30 mg and 120 mg tablets in children with Chagas disease. In this blinded, controlled study...